Continental Advisors LLC Has $537,000 Position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Continental Advisors LLC lowered its holdings in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 69.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,400 shares of the financial services provider’s stock after selling 12,200 shares during the period. Continental Advisors LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $537,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of IBB. Harbor Advisory Corp MA raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 0.5% in the third quarter. Harbor Advisory Corp MA now owns 35,156 shares of the financial services provider’s stock valued at $3,498,000 after buying an additional 180 shares during the last quarter. 1 North Wealth Services LLC bought a new position in shares of iShares Nasdaq Biotechnology ETF in the third quarter valued at about $1,566,000. Capital Investment Advisors LLC raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 3.4% in the third quarter. Capital Investment Advisors LLC now owns 11,711 shares of the financial services provider’s stock valued at $1,165,000 after buying an additional 381 shares during the last quarter. Connecticut Wealth Management LLC bought a new position in shares of iShares Nasdaq Biotechnology ETF in the third quarter valued at about $244,000. Finally, FormulaFolio Investments LLC raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 4.1% in the third quarter. FormulaFolio Investments LLC now owns 4,732 shares of the financial services provider’s stock valued at $471,000 after buying an additional 186 shares during the last quarter. Hedge funds and other institutional investors own 79.01% of the company’s stock.

Separately, ValuEngine cut iShares Nasdaq Biotechnology ETF from a “buy” rating to a “hold” rating in a report on Tuesday, October 22nd.

Shares of iShares Nasdaq Biotechnology ETF stock traded up $1.41 during trading on Monday, reaching $107.00. The company’s stock had a trading volume of 99,550 shares, compared to its average volume of 2,469,167. The stock has a 50-day moving average price of $102.12 and a two-hundred day moving average price of $104.73. iShares Nasdaq Biotechnology ETF has a one year low of $89.01 and a one year high of $116.25.

The firm also recently declared a — dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were issued a $0.0715 dividend. The ex-dividend date of this dividend was Tuesday, September 24th. This represents a dividend yield of 0.1%.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Recommended Story: Why does the United States have a lingering trade deficit?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.